A Calgary-based company called Solvet has received approval from the U.S. Food and Drug Administration (FDA) to market its equine ivermectin product in the United States to combat screwworm. Solvet’s CEO, Lionel Gibbs, explained that their ivermectin liquid for horses is unique as it is aqueous-based, concentrated, and easier to administer compared to traditional paste forms.
Established in 2009 by two former University of Calgary professors, Solvet has evolved into one of Canada’s leading veterinary pharmaceutical companies. Ivermectin, a well-known anti-parasitic drug, is commonly used to combat various parasites, including screwworm, a type of fly native to parts of North America.
Screwworm flies lay eggs on open wounds of animals such as horses and cattle, leading to larvae infestation and potential severe consequences. Despite successful eradication efforts in North America using the sterile insect technique, screwworm has reappeared in Central America, Mexico, and parts of the southern United States.
In response to the resurgence of screwworm, Solvet’s ivermectin liquid received emergency use authorization from the FDA specifically for screwworm prevention in horses. This temporary approval aims to address the immediate threat posed by screwworm infestations and protect livestock welfare.
Veterinarian John Gilleard from the University of Calgary emphasized the importance of responsible usage of ivermectin to prevent resistance in parasites and environmental impacts. While Canada currently faces a low risk of screwworm presence, authorities continue monitoring the situation closely and collaborating with U.S. counterparts.
For Solvet, this development not only underscores their commitment to animal health but also presents a strategic opportunity for expansion, particularly in the U.S. market. Gibbs highlighted the potential economic benefits for Alberta through increased investment and research funding stemming from Solvet’s involvement in addressing the screwworm threat.